Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Consolidated Net Income (2010 - 2026)

Exelixis (EXEL) posted quarterly Consolidated Net Income of $210.5 million for Q2 2026, up 31.86% year-over-year from $159.6 million in Q2 2025, and down 13.93% quarter-over-quarter from $244.5 million in Q1 2026.

Analysis

Exelixis (EXEL) Consolidated Net Income (2010 - 2026) Analysis & Trends

Exelixis' Consolidated Net Income history runs 17 years deep, the most recent figure standing at $210.5 million for Q2 2026.

  • In Q2 2026, Consolidated Net Income rose 31.86% year-over-year to $210.5 million; the TTM figure through Apr 2026 stood at $833.4 million (up 29.5% YoY), while the FY2026 annual figure was $782.6 million, up 50.13% from the prior year.
  • Consolidated Net Income for Q2 2026 stood at $210.5 million, down from $244.5 million in the prior quarter.
  • The five-year high for Consolidated Net Income was $244.5 million in Q1 2026, with the low at -$30.2 million in Q4 2022.
  • The 5-year median for Consolidated Net Income is $85.5 million (2023), against an average of $112.0 million.
  • The sharpest annual moves came in 2022 and 2024: Consolidated Net Income tumbled 131.71% in 2022, then soared 11232.66% in 2024.
  • Exelixis' Consolidated Net Income stood at -$30.2 million in 2022, then jumped by 383.43% to $85.5 million in 2023, then soared by 37.95% to $118.0 million in 2024, then soared by 64.09% to $193.6 million in 2025, then grew by 8.72% to $210.5 million in 2026.
  • Business Quant data shows EXEL's Consolidated Net Income at $210.5 million in Q2 2026, $244.5 million in Q1 2026, and $193.6 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn 212.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 212.05 Mn
Apr 3, 2026 210.47 Mn
Jan 2, 2026 244.53 Mn
Oct 3, 2025 193.58 Mn
Jul 4, 2025 184.85 Mn
Apr 4, 2025 159.62 Mn
Jan 3, 2025 139.86 Mn
Sep 27, 2024 117.97 Mn
Jun 28, 2024 226.12 Mn
Mar 29, 2024 37.32 Mn
Dec 29, 2023 85.52 Mn
Sep 29, 2023 1.04 Mn
Jun 30, 2023 81.18 Mn
Mar 31, 2023 40.03 Mn
Dec 30, 2022 -30.17 Mn
Sep 30, 2022 73.21 Mn
Jul 1, 2022 70.67 Mn
Apr 1, 2022 68.57 Mn
Dec 31, 2021 95.17 Mn
Oct 1, 2021 38.20 Mn